Business ❯ Finance ❯ Corporate Finance

Pharmaceuticals

Financial Performance Novo Nordisk Pfizer GSK Eli Lilly Earnings Reports AstraZeneca Dr Reddy's Laboratories Sales Performance Merck

BioCryst Cuts Internal Discovery After Q2 ORLADEYO Gains and Pediatric Rollout

The move is meant to lower R&D costs, preserve cash, and shift future innovation to external partners as late-stage trials continue.

Pfizer Raises 2026 Revenue Floor After Q2 Beat as Covid Sales Fall

Vertex Raises 2026 Revenue Range on Cystic Fibrosis Drug Strength

Dupixent Surge Lets Sanofi Reset Strategy as Regeneron Posts Strong Quarter

GSK Reports Q2 Beat and Unveils £1.9 Billion Savings Plan

AstraZeneca Beats Q2 Estimates and Reaffirms 2026 Guidance

argenx Posts $1.52 Billion Quarter as VYVGART Readouts Loom

Novartis Returns to Sales Growth as New Drugs Offset Entresto Slump

Johnson & Johnson Beats Q2 Estimates and Lifts Full‑Year Outlook

Fennec Q1 Sales Climb 73% to $15.1 Million on PEDMARK Momentum

Verrica Reports $5 Million Q1 Revenue as Wycanth Grows and Phase 3 Wart Program Advances

Novo Nordisk Lifts Outlook After Wegovy Pill Fuels Q1 Beat

Pfizer Beats Q1 Forecasts as Newer Drugs Offset COVID Slide

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

Regeneron Tops Q1 Estimates as Dupixent and Libtayo Outpace Eylea

ANI Pharmaceuticals Posts Record Quarter as Rare-Disease Drugs Power 29.6% Sales Jump

Collegium Reports Record 2025 Results, Projects Strong 2026 for Jornay as Hikma Generic Nears

Almirall Tops €1.1 Billion in 2025 Sales as Profit Quadruples, Issues 2026 Guidance

AstraZeneca Posts Strong 2025 Results, Sees Further Growth in 2026

Zydus, Aurobindo Report Q3 Profit Growth as U.S. Sales Climb and Labour-Code Charges Weigh